Is a diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose

Circulation: Cardiovascular Genetics

Volumn 7, Issue 2, 2014, Pages 199-205

  Cooper DeHoff, Rhonda M ^a,b   Hou, Wei ^c   Weng, Liming ^a,b   Baillie, Rebecca A ^d   Beitelshees, Amber L ^e   Gong, Yan ^a,b   Shahin, Mohamed H A ^a,b   Turner, Stephen T ^f   Chapman, Arlene ^g   Gums, John G ^a,b   Boyle, Stephen H ^h   Zhu, Hongjie ^h   Wikoff, William R ⁱ   Boerwinkle, Eric ^j   Fiehn, Oliver ⁱ   Frye, Reginald F ^e   Kaddurah Daouk, Rima ^h   Johnson, Julie A ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d Rosa and Co LLC   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

Atherosclerosis; MicroRNAs; Myocardial infarction; Plasma

Indexed keywords

AMINO ACID; ATENOLOL; BRANCHED CHAIN AMINO ACID TRANSAMINASE 1; GLUCOSE; INSULIN; ISOLEUCINE; LEUCINE; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; TYROSINE; UNCLASSIFIED DRUG; VALINE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

EID: 84903603874     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000421     Document Type: Article

References (42)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Bombelli M, Facchetti R, Sega R, Carugo S, Fodri D, Brambilla G, et al. Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage. Hypertension. 2011;58:1029-1035.
3. Hayden MR, Sowers Jr. Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens. 2008;2:239-266.
4. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med. 2008;121:519-524. (Pubitemid 351699262)
5. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215-2221.
6. Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55:61-68.
7. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta- blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117:2706-2715.
8. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207. (Pubitemid 46111014)
9. Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P, et al STAR Investigators. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009;11:177-187.
10. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653-683. (Pubitemid 351738167)
11. Trupp M, Zhu H, Wikoff WR, Baillie RA, Zeng ZB, Karp PD, et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One. 2012;7:e38386.
12. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448-453.
13. Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36:648-655.
14. Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, et al.; INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006;98:890-894. (Pubitemid 44402257)
15. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al; LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-1886.
16. Rampersaud E, Damcott CM, Fu M, Shen H, McArdle P, Shi X, et al. Identification of novel candidate genes for type 2 diabetes from a genome- wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes. 2007;56:3053-3062. (Pubitemid 350223642)
17. Rich SS, Bowden DW, Haffner SM, Norris JM, Saad MF, Mitchell BD, et al Insulin Resistance Atherosclerosis Study Family Study. Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2004;53:1866-1875. (Pubitemid 38857046)
18. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2011;89:97-104.
19. Levitzky YS, Pencina MJ, D'Agostino RB, Meigs JB, Murabito JM, Vasan RS, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008;51:264-270.
20. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper- DeHoff RM, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009;157:442-449.
21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495. (Pubitemid 38680001)
22. Fiehn O, Wohlgemuth G, Scholz M, Kind T, Lee do Y, Lu Y, et al. Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J. 2008;53:691-704. (Pubitemid 351224695)
23. Scholz M, Fiehn O. Setupx: a public study design database for metabolomic projects. Pac Symp Biocomput. 2007:169-180.
24. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014;37(Suppl 1):S14-S80.
25. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care. 2009;32:1678-1683.
26. Galwey NW. A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests. Genet Epidemiol. 2009;33:559-568.
27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population- based linkage analyses. Am J Hum Genet. 2007;81:559-575. (Pubitemid 47330214)
28. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissén M, et al; Botnia study group. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166-174. (Pubitemid 40105109)
29. Kim JA, Wei Y, Sowers Jr. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102:401-414. (Pubitemid 351651099)
30. Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281:811-816.
31. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15:606-614.
32. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311-326.
33. Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3:207-214.
34. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/ p70 S6 kinase pathway: a negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001;276:38052-38060.
35. Shah SH, Svetkey LP, Newgard CB. Branching out for detection of type 2 diabetes. Cell Metab. 2011;13:491-492.
36. Hsueh WC, Mitchell BD, Aburomia R, Pollin T, Sakul H, Gelder Ehm M, et al. Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study. Diabetes Care. 2000;23:595-601. (Pubitemid 30321536)
37. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
38. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998;11:1258-1265.
39. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236. (Pubitemid 39473160)
40. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591-596. (Pubitemid 43261924)
41. 2010 top 200 generic drugs by total prescription. 2011;2012:http:// drugtopics. modernmedicine.com/drugtopics/data/articlestandard//drugtopics/ 252011/727243/article.pdf.
42. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874-887.